Drug-drug interactions: Proof of relevance (part II): Cause of tolerability problems or noncompliance

Journal of Psychiatric Practice

Volumn 11, Issue 6, 2005, Pages 397-401

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; FLUOXETINE; PAROXETINE; RISPERIDONE;

DRUG EFFECT; DRUG METABOLISM; EXTRAPYRAMIDAL SYNDROME; HUMAN; MORBIDITY; MORTALITY; PRESCRIPTION; RECEPTOR BINDING; REVIEW; SEIZURE; SUDDEN DEATH; SUICIDE;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MENTAL DISORDERS; RISPERIDONE; SEROTONIN UPTAKE INHIBITORS; TREATMENT REFUSAL;

EID: 28044457432     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200511000-00006     Document Type: Review

References (14)

1. Preskorn SH. Drug-drug-interactions: Proof of relevance (Part I). J Psychiatr Pract 2005;11:116-22.
2. Preskorn SH. .The difference between the formal and the functional dose: The case of the patient on thioridazine and fluvoxamine. J Psychiatr Pract 2005;11:192-6.
3. Levy RH, Thummel KE, Trager WF, et al. Metabolic drug interactions. Philadelphia: Lippincott, Williams & Wilkins, 2000.
4. Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
5. Preskorn SH. Classification of neuropsychiatric medication by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions. J Psychiatr Pract 2003;9:376-84.
6. Preskorn SH. De-spinning in vitro data. Journal of Practical Psychiatry and Behavioral Health 199;5:283-7.
7. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
8. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27.
9. Preskorn SH. "I don't see 'em." Journal of Practical Psychiatry and Behavioral Health 1997;3:302-7.
10. Preskorn SH. Fatal drug-drug interactions as a differential consideration in apparent suicides. J Psychiatr Pract 2002;8:233-8.
11. Preskorn SH. Clinical pharmacology case conference: A suicide attempt? J Psychiatr Pract 2002; 8:306-10.
12. Preskorn SH. Polypharmacy in a patient with refractory major depression: Part I: The case. J Psychiatr Pract 2002;8:370-6.
13. Preskorn SH. A message from Titanic. Journal of Practical Psychiatry and Behavioral Health 1998;4:236-42.
14. Preskorn SH. Do you believe in magic? Journal of Practical Psychiatry and Behavioral Health 1997;3:99-103.